Wash U Medical Center offers new gene-altering treatment for some types of blood cancer – St. Louis Public Radio
St. Louis Public Radio |
Wash U Medical Center offers new gene-altering treatment for some types of blood cancer
St. Louis Public Radio Like other immunotherapy drugs, doctors don’t know yet if most patients treated with Yescarta will stay in remission for the rest of their lives. But Ghobadi said he looks forward to seeing more immunotherapy drugs become available to cancer patients. |
Philadelphia Business Journal |
Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider
Zacks.com Gilead Sciences’s (GILD – Free Report) Yescarta, a cell-based gene therapy, gained approval for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of … FDA approves second gene-altering treatment for cancerPhiladelphia Business Journal US approves second gene therapy against cancerDeathRattleSports.com FDA Approves Second CAR-T Therapy In US To Gilead’s Kite PharmaPharmaceutical Online (press release) |
WKSU News |
Gilead Drug Approval Fuels Interest in CAR–T Space: 3 Stocks to Consider
Zacks.com Interest in the CAR-T (chimeric antigen receptor T cells) space continues to build up with the FDA giving its nod to the second CAR-T therapy last week. Gilead Sciences’s (GILD – Free Report) Yescarta, a cell-based gene therapy, gained approval for the … Gene Therapy Ushers In a New Era in Cancer TreatmentWKSU News The Floodgates are Open: FDA Approves Second Cancer Gene TherapyAmerican Council on Science and Health FDA approves second gene therapy for cancerBioNews Motley Fool –East Idaho News –pharmabiz.com all 17 news articles » |
|
3 Gene Therapy Stocks That Could Make You Rich
Motley Fool A pipeline full of similar therapies, and the means to develop them, earns Gilead a spot on this list, but you should know that today’s best gene therapy stocks aren’t limited to the field of cancer. While bluebird bio, Inc. (NASDAQ:BLUE) has cancer … AveXis, Inc. (AVXS) Stake Boosted by Nationwide Fund AdvisorsDispatch Tribunal |